(19)
(11) EP 3 442 532 A1

(12)

(43) Date of publication:
20.02.2019 Bulletin 2019/08

(21) Application number: 17782552.8

(22) Date of filing: 17.04.2017
(51) International Patent Classification (IPC): 
A61K 31/47(2006.01)
A61K 9/48(2006.01)
A61P 35/00(2006.01)
A61K 9/20(2006.01)
A61K 31/436(2006.01)
(86) International application number:
PCT/JP2017/015461
(87) International publication number:
WO 2017/179739 (19.10.2017 Gazette 2017/42)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 15.04.2016 JP 2016081787
15.04.2016 US 201662322916 P

(71) Applicant: Eisai R&D Management Co., Ltd.
Tokyo 112-8088 (JP)

(72) Inventor:
  • KREMER, Alton
    Woodcliff Lake NJ 07677 (US)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)

   


(54) TREATMENT OF RENAL CELL CARCINOMA WITH LENVATINIB AND EVEROLIMUS